DavidAllenSmithMD

Oncology • Vancouver, WA

Physician

Join to view full profile

Dr. Smith is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Smith's full profile

Already have an account?

Office
210 Se 136th Ave
Vancouver, WA 98684
Phone+1 360-944-9889

Fax+1 360-944-9686

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1991 - 1994
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 1987 - 1990
University of Washington School of MedicineClass of 1987

Certifications & Licensure

WA State Medical License 1994 - 2025
OR State Medical License 1997 - 2021
MD State Medical License 1989 - 1995

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure) Start of enrollment: 2011 Aug 01
Unknown status
Not Applicable
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Start of enrollment: 2011 Apr 01
Completed
Phase 1, Phase 2
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors Start of enrollment: 2012 Apr 01
Completed
Phase 1
Applying Platelet Rich Plasma (PRP) Gel to Acute Deep Partial Thickness Thermal Injuries Start of enrollment: 2014 Jul 01
Unknown status
Phase 1
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Start of enrollment: 2015 Jun 26
Completed
Phase 1, Phase 2
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Start of enrollment: 2015 Oct 05
Terminated
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

51 citations
Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cel...
David Smith, Paul Conkling, Donald A. Richards, John Nemunaitis, Thomas E. Boyd
Cancer Immunology, Immunotherapy. 2014-04-27
8 citations
nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC.
Corey J. Langer, Edward S. Kim, Eric C. Anderson, Robert M. Jotte, Manuel Modiano
Frontiers in Oncology. 2018-07-24